Abstract
Purpose:To describe a case of ophthalmic artery occlusion and complete ophthalmoplegia after intralesional injection of a sclerosing agent into a subcutaneous hemangioma on the forehead.Case Report:A 16-year-old girl underwent direct injection of 3 mL of sodium tetradecyl sulfate (Fibrovein) emulsion 1% (10 mg/mL) with a 23-gauge needle into a subcutaneous hemangioma on the forehead. Immediately after the injection, she developed sudden loss of vision and lid swelling of the left eye. Her visual acuity in the left eye became no light perception. Her left eye also developed a dilated pupil, ptosis, and complete external ophthalmoplegia. Funduscopy of the left eye revealed signs of central retinal artery occlusion. Magnetic resonance imaging of the orbit showed thickening of the medial and lateral rectus muscles of the left eye. Magnetic resonance venography of the brain was normal with no evidence of cavernous venous thrombosis. After 3 months, her ptosis and ophthalmoplegia resolved but her visual acuity remained no light perception.Conclusion:Persistent total visual loss should be kept in mind as a disastrous complication of sclerosing therapy in a patient with facial hemangioma.
Highlights
Ocular complications following non‐ophthalmic procedures are rare but may be devastating
Quick Response Code: Website: www.jovr.org the arterial lumens around the visual system and gives rise to ischemic optic neuropathy, central retinal artery occlusion, or cortical ischemia.[2]
In 2009, Matsuo et al described visual loss caused by occlusion of the central retinal and posterior ciliary arteries following intralesional injection of a sclerosing agent into a glabellar hemangioma in an 18‐year‐old male patient.[5]
Summary
Ocular complications following non‐ophthalmic procedures are rare but may be devastating. Occlusion of the ophthalmic artery and ophthalmoplegia following sclerotherapy is very rare.[3] Ophthalmic artery occlusion following facial sclerosing therapy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
